Last reviewed · How we verify
Trifluridine and Tipiracil Hydrochloride — Competitive Intelligence Brief
phase 1
Live · refreshed every 30 min
Target snapshot
Trifluridine and Tipiracil Hydrochloride (trifluridine-and-tipiracil-hydrochloride) — Pfizer Inc.. Trifluridine and tipiracil hydrochloride inhibit thymidylate synthase and DNA synthesis, leading to cell death in cancer cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trifluridine and Tipiracil Hydrochloride TARGET | trifluridine-and-tipiracil-hydrochloride | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trifluridine and Tipiracil Hydrochloride CI watch — RSS
- Trifluridine and Tipiracil Hydrochloride CI watch — Atom
- Trifluridine and Tipiracil Hydrochloride CI watch — JSON
- Trifluridine and Tipiracil Hydrochloride alone — RSS
Cite this brief
Drug Landscape (2026). Trifluridine and Tipiracil Hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/trifluridine-and-tipiracil-hydrochloride. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab